Company: OFIX
Filing Date: 2025-04-30
Form Type: DEF 14A
Source: 0000950170-25-061062
Chunk: 49

Company: Orthofix Medical Inc.
Filing Date: 2025-04-30
Form: DEF 14A
Chunk 49
---
 below:

| Name                      | 2024 Base 
 Salary    
 Amount    |         |     | Target Bonus 
 Percentage   
 of Salary    | Weighted    
 Percent     
 Achievement | Total Annual   
 Incentive Plan 
 Bonus          |         |
|:--------------------------|:----------|--------:|:----|:-------------|:------------|:---------------|--------:|
| Massimo Calafiore         | $         | 825,000 |     | 110%         | 102.1%      | $              | 926,558 |
| Julie Andrews             | $         | 475,000 |     | 70%          | 102.1%      | $              | 339,483 |
| J. Andrés Cedrón          | $         | 470,000 |     | 70%          | 102.1%      | $              | 335,909 |
| Geoffrey C. Gillespie (1) | $         | 325,599 |     | 43%          | 102.1%      | $              | 141,547 |
| Max Reinhardt             | $         | 480,000 |     | 70%          | 89.7%       | $              | 301,392 |
| Lucas Vitale              | $         | 460,000 |     | 70%          | 102.1%      | $              | 328,762 |

(1) Amounts shown for Mr. Gillespie reflect changes to his compensation effective March 4, 2024, when he was employed by the Company as Chief Accounting Officer. Payouts to the named executive officers under the annual incentive program are reflected in column (g) of the “Summary Compensation Table.” Long-Term Equity-Based Incentives Long-Term Incentive Plan – 2012 LTIP and SeaSpine 2015 Plan In accordance with our Executive Compensation Guiding Principles, the creation of sustainable shareholder value by means of equity incentive awards is a very important element of the total compensation provided to executives at Orthofix. Our primary equity compensation plan is the 2012 LTIP, which was originally approved by our shareholders at the Company’s 2012 annual meeting, with amendments further increasing the number of shares authorized under the plan being approved by our shareholders, most recently at the Company’s 2024 annual meeting. In connection with the Company’s merger with SeaSpine, the Company assumed awards outstanding under the Sea